tiprankstipranks
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
US Market

VYNE Therapeutics (VYNE) Technical Analysis

Compare
1,827 Followers

Technical Sentiment

Overall Consensus
Strong Buy
15Bullish
4Neutral
3Bearish
Technical Analysis Consensus
Buy
4Bullish
4Neutral
2Bearish
Moving Average Consensus
Strong Buy
11Bullish
0Neutral
1Bearish
VYNE Therapeutics’s (VYNE) Moving Averages Convergence Divergence (MACD) indicator is -0.05, suggesting VYNE Therapeutics is a Sell.
VYNE Therapeutics’s (VYNE) 20-Day exponential moving average is 2.58, while VYNE Therapeutics’s (VYNE) share price is $2.74, making it a Buy.
VYNE Therapeutics’s (VYNE) 50-Day exponential moving average is 2.67, while VYNE Therapeutics’s (VYNE) share price is $2.74, making it a Buy.

VYNE Therapeutics (VYNE) Pivot Points

Feb 23, 2025, 12:25 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
2.28
2.39
2.55
2.66
2.81
2.92
3.08
Fibonacci
2.39
2.49
2.56
2.66
2.76
2.82
2.92
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

VYNE Therapeutics (VYNE) Moving Averages

Feb 23, 2025, 12:25 AM
Period
Simple
Exponential
MA5
2.59Buy
2.62Buy
MA10
2.52Buy
2.57Buy
MA20
2.51Buy
2.58Buy
MA50
2.77Sell
2.67Buy
MA100
2.66Buy
2.62Buy
MA200
2.37Buy
2.48Buy
VYNE Therapeutics’s (VYNE) 10-Day exponential moving average is 2.57, while VYNE Therapeutics’s (VYNE) share price is $2.74, making it a Buy.
VYNE Therapeutics’s (VYNE) 100-Day exponential moving average is 2.62, while VYNE Therapeutics’s (VYNE) share price is $2.74, making it a Buy.
VYNE Therapeutics’s (VYNE) stock price is $2.74 and VYNE Therapeutics’s (VYNE) 50-day simple moving average is 2.77, creating a Sell signal.
VYNE Therapeutics’s (VYNE) stock price is $2.74 and VYNE Therapeutics’s (VYNE) 100-day simple moving average is 2.66, creating a Buy signal.
VYNE Therapeutics’s (VYNE) stock price is $2.74 and VYNE Therapeutics’s (VYNE) 200-day simple moving average is 2.37, creating a Buy signal.

VYNE Therapeutics (VYNE) Technical Indicators

Feb 23, 2025, 12:25 AM
Name
Value
Implied Action
RSI (14)
56.13
Neutral
STOCH (9,6)
74.68
Neutral
STOCHRSI (14)
75.19
Neutral
MACD (12,26)
-0.05
Sell
ADX (14)
14.22
Buy
Williams %R
-28.99
Buy
CCI (14)
138.91
Sell
ATR (14)
0.24
-
Ultimate Oscillator
50.31
Neutral
ROC
16.60
Buy
VYNE Therapeutics’s (VYNE) Relative Strength Index (RSI) is 56.13, creating a Neutral signal.
VYNE Therapeutics’s (VYNE) Trend Strength Indicator (ADX) is 14.22, creating a Buy signal.
VYNE Therapeutics’s (VYNE) Commodity Channel Index (CCI) is 138.91, creating a Sell signal.
VYNE Therapeutics’s (VYNE) Price Rate of Change (ROC) is 16.60, creating a Buy signal.

FAQ

Is VYNE a Buy, Hold, or Sell?
Based on VYNE’s technical indicators, VYNE is a Strong Buy.
    What is VYNE’s RSI (14)?
    VYNE’s RSI (14) is 56.13, which suggests VYNE is a Neutral.
      What is VYNE’s MACD?
      VYNE’s MACD is -0.05, which suggests VYNE is a Sell.
        What is VYNE’s 5-day moving average?
        VYNE’s 5-day moving average is 2.59, which suggests VYNE is a Buy.
          What is VYNE’s 20-day moving average?
          VYNE 20-day moving average is 2.51, which suggests VYNE is a Buy.
            What is VYNE’s 50-day moving average?
            VYNE’s 50-day moving average is 2.77, which suggests VYNE is a Sell.
              What is VYNE’s 200-day moving average?
              VYNE’s 200-day moving average is 2.37, which suggests VYNE is a Buy.
                What is VYNE’s Williams % R (14)?
                VYNE’s Williams % R (14) is -28.99, which suggests VYNE is a Buy.
                  What is VYNE’s CCI (14)?
                  VYNE’s CCI (14) is 138.91, which suggests VYNE is a Sell.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis